Orthocell Ltd · ASX:OCC
Orthocell — Investor Presentation (March 2015)
17 slides from Orthocell's investor presentation, Mar 17, 2015
Slide 1: Advancing Tissue Repair and Regeneration
For personal use only Advancing Tissue Repair and Regeneration Investor Presentation ASX: OCC Paul Anderson Managing Director
Slide 2: Disclaimer
Disclaimer For personal use only This presentation prepared by Orthocell Pty Ltd ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall ther
Slide 3: Company Information
Company Information For personal use only ASX: OCC Orthocell is a world leading Share price $0.36 commercial stage regenerative Shares on issue 82,500,000 medicine company Market cap $30 million 5,912,500 (exercisable $0.50) Options outstanding 3,520,000 (exercisable @ $0.62) •Orthocell’s lead produ
Slide 4: Year highlights
Year highlights For personal use only • Increased number of patients treated with Ortho-ATI™ - now more than 270 patients treated with Ortho-ATI™ • First international sales of Ortho-ATI™ in Hong Kong • Completed first human pilot trial of Celgro™ • Presented successful 4.5 year data on Ortho-ATI™ f
Slide 5: Regenerative medicine market
Regenerative medicine market For personal use only Regenerative medicine is one of the fastest growing health markets driven by: - an aging population - increasing participation in sports activities - growing trend of minimally invasive procedures - advancement in orthopedic product technologies U.S
Slide 6: Regen medicine corporate market heating up
Regen medicine corporate market heating up For personal use only Notable Deals 2013/14 Financings 2013/14 Source: Alliance for Regenerative Medicine Annual Report 2014 Source: Alliance for Regenerative Medicine Annual Report 2014
Slide 7: Collagen Scaffold - CelGro™
Collagen Scaffold - CelGro™ For personal use only • CelGro™ is a superior tissue regeneration technology that: - has high mechanical strength and pliability - has no foreign DNA and is pure - is very cell friendly • Multiple applications: - tendon augmentation and repair - bone repair and regenerati
Slide 8: Global Celgro™ market is significant
Global Celgro™ market is significant For personal use only • Celgro™ is initially being developed for: - Rotator Cuff repair - $1.8BB annual market with 45% revision rate for existing surgeries and no strong and resorbable scaffold available; and - Vaginal Wall prolapse - $800MM annual market with N
Slide 9: Ortho-ATI™ - tendon regeneration
Ortho-ATI™ - tendon regeneration For personal use only Proprietary method for expanding and cultivating tendon stem cells (Tenocytes) TGA approved Minimally invasive Tendon biopsy GMP process to reinjection of from patient to expand and tenocyte cells at collect tendon cultivate site of tendon stem
Slide 10: Global Ortho-ATI™ market is significant
Global Ortho-ATI™ market is significant For personal use only • Ortho-ATI™ has been applied to most tendon injuries, but regulatory approval in Australia is initially focused on: - Lateral Epicondylitis - $700MM market largely dependent on surgery to address recalcitrant long term tendon damage; - G
Slide 11: Key Applications of Ortho-ATI™ - Lateral Epicondylitis
Key Applications of Ortho-ATI™ For personal use only Lateral Epicondylitis (Tennis Elbow) - Ortho-ATI™ can structurally repaired tendon tissue in patients with severe tennis elbow - Long term data (3-5yrs) demonstrates durability and effectiveness
Slide 12: Key Applications of Ortho-ATI™ - Gluteal Tendinopathy
Key Applications of Ortho-ATI™ For personal use only Gluteal Tendinopathy (Hip) - Common injury in middle aged women with debilitating affect on quality of life and limited surgical success - Ortho-ATI™ has demonstrated significant clinical improvement at 3 months, maintained to 24 months in treatme
Slide 13: Tendon in a lab – next generation
Tendon in a lab – next generation For personal use only Strain (%) 6 1 2 3 4 5 6 Time (s)
Slide 14: Growing recognition
Growing recognition For personal use only • Foster Stockbroking (23.09.2014)* ‘With two proprietary , mass market regenerative medicine treatments on the cusp of global commercialisation, we believe OCC is well positioned to transition into a significant player in the Biotech sector’ • Smart Investo
Slide 15: Upcoming Milestones 2015
Upcoming Milestones 2015 For personal use only • Commence CelGro™ guided bone repair trial – Q2 2015 • Commence CelGro™ Rotator Cuff clinical trial – Q2 2015 • Commence Ortho-ATI™ Lateral Epicondylitis trial – Q3 2015 • Ortho-ATI trial data Achilles – Q2 2015 • Finalise Bone Support AB collaboration
Slide 16: Investment Highlights
Investment Highlights For personal use only Approved treatments with First tendon and ligament regeneration product strong clinical evidence approved in a major market The market for musculoskeletal conditions in U.S. EU Significant unmet medical and Japan targeted by Orthocell therapies exceeds $7B
Slide 17: Thank you
For personal use only Advancing Tissue Repair and Regeneration Thank you ASX: OCC Paul Anderson Managing Director